|
[1] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management and treatment of heptocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese).中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志,2017,33(8):1419-1431.
|
|
[2] TATETSU H,KONG NR,CHONG G,et al. SALL4,the missing link between stem cells,development and cancer[J].Gene,2016,584(2):111-119.
|
|
[3] MA C,WANG F,HAN B,et al. SALL1 functions as a tumor suppressor in breast cancer by regulating cancer cell senescence and metastasis through the NuRD complex[J]. Mol Cancer,2018,17(1):78.
|
|
[4] TSUNEKAZU O,AKIHIDE K,SEI K,et al. Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells[J]. Gastroenterology,2009,136(3):1000-1011.
|
|
[5] MA YP,CUI W,YANG JC,et al. SALL4,a novel oncogene,is constitutively expressed in human acute myeloid leukemia(AML)and induces AML in transgenic mice[J]. Blood,2006,108(8):2726-2735.
|
|
[6] LI A,JIAO Y,YONG KJ,et al. SALL4 is a new target in endometrial cancer[J]. Oncogene,2015,34(1):63-72.
|
|
[7] YONG KJ,GAO C,LIM JSJ,et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma[J]. N Engl J Med,2013,368(24):2266-2276.
|
|
[8] YAKABOSKI E,JARES A,MA Y. Stem cell gene SALL4 in aggressive hepatocellular carcinoma:A cancer stem cell-specific target?[J]. Hepatology,2014,60(1):419-421.
|
|
[9] MASUDA S,SUZUKI K,IZPISUA BELMONTE JC. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma[J]. N Engl J Med,2013,369(12):1170-1172.
|
|
[10] OIKAWA T,KAMIYA A,ZENIYA M,et al. Sal-like protein 4(SALL4),a stem cell biomarker in liver cancers[J]. Hepatology,2013,57(4):1469-1483.
|
|
[11] HAN SX,WANG JL,GUO X,et al. Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma[J]. J Immunol Res,2014,2014:262385.
|
|
[12] SHIBAHARA J,ANDO S,HAYASHI A,et al. Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma[J]. Springerplus,2014,3:721.
|
|
[13] LIU TC,VACHHARAJANI N,CHAPMAN WC,et al. SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event:A study of 236 cases[J]. Am J Surg Pathol,2014,38(7):966-972.
|
|
[14] ZENG SS,YAMASHITA T,KONDO M,et al. The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma[J]. J Hepatol,2014,60(1):127-134.
|
|
[15] PARK H,LEE H,SEO AN,et al. SALL4 expression in hepatocellular carcinomas is associated with EpCAM-positivity and a poor prognosis[J]. J Pathol Transl Med,2015,49(5):373-381.
|
|
[16] JUNG YK,JANG K,PAIK SS,et al. Positive immunostaining of Sal-like protein 4 is associated with poor patient survival outcome in the large and undifferentiated Korean hepatocellular carcinoma[J]. Ann Surg Treat Res,2016,91(1):23-28.
|
|
[17] YIN F,HAN X,YAO SK,et al. Importance of SALL4 in the development and prognosis of hepatocellular carcinoma[J].World J Gastroenterol,2016,22(9):2837-2843.
|
|
[18] WANG H,KOHASHI K,YOSHIZUMI T,et al. Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma[J]. Hum Pathol,2017,64:69-75.
|
|
[19] LIU BH,JOBICHEN C,CHIA CSB,et al. Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide[J]. Proc Natl Acad Sci U S A,2018,115(30):e7119-e7128.
|
|
[20] DENG G,ZHU L,HUANG F,et al. SALL4 is a novel therapeutic target in intrahepatic cholangiocarcinoma[J]. Oncotarget,2015,6(29):27416-27426.
|
|
[21] MOEINI A,SIA D,ZHANG ZY,et al. Mixed hepatocellular cholangiocarcinoma tumors:Cholangiolocellular carcinoma is a distinct molecular entity[J]. J Hepatol,2017,66(5):952-961.
|
|
[22] TANAKA Y,AISHIMA S,KOHASHI K,et al. Spalt-like transcription factor 4 immunopositivity is associated with epithelial cell adhesion molecule expression in combined hepatocellular carcinoma and cholangiocarcinoma[J]. Histopathology,2016,68(5):693-701.
|
|
[23] ZHOU WY,ZOU BK,LIU LS,et al. MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4[J]. Oncotarget,2016,7(45):74059-74073.
|
|
[24] LI Y,LI RH,FU XY,et al. MicroRNA-33b inhibits cell proliferation in hepatocellular carcinoma via targeting SALL4[J]. J Cent South Univ(Med Sci),2016,41(9):905-910.(in Chinese)李艳,李荣华,符小玉,等. MicroRNA-33b通过靶向调控SALL4的表达抑制肝细胞癌细胞增殖[J].中南大学学报(医学版),2016,41(9):905-910.
|
|
[25] SUN C,LAN P,HAN Q,et al. Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion[J]. Nat Commun,2018,9(1):1241.
|
DownLoad: